Europe PMC

This narrative review elucidates the impact of biologics and small-molecule inhibitors on bone metabolism and cardiovascular risk in patients with psoriasis. Psoriasis is a systemic immune-mediated disorder characterized by a "Calcification Paradox"-the simultaneous occurrence of skeletal bone loss and vascular calcification. We explore the molecular mechanisms of the "Bone-Vascular Axis", highlighting how the IL-23/IL-17 axis disrupts the RANKL/OPG balance and drives the osteogenic transdiffere

Available evidence reveals markedly divergent metabolic signatures across biologics and small-molecule inhibitors, highlighting the need for further investigations. To address this knowledge gap, we performed a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies in patients with psoriasis or psoriatic arthritis (PsA) to quantify the short- and long-term effects of targeted therapies on lipid profiles. PubMed, Embase, and Cochrane databases were se

Background Research suggests that healthcare professionals find it more difficult to correctly diagnose dermatological conditions in the nonwhite patient demographic. People of colour experience higher rates of delayed and misdiagnosis, contributing to an increased mortality risk and increased health inequalities that remain widespread throughout the health care setting. This study aimed to investigate podiatry student's ability, confidence, approaches and perceptions in diagnosing dermatology p

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

The psoriatic arthritis phenotype has evolved over the past several decades. The original description of 5 clinical patterns has been expanded into 6 domains including peripheral arthritis (which includes 3 of the patterns described by Moll and Wright namely distal, oligoarticular and polyarticular), axial disease, dactylitis, enthesitis, skin and nails. In this article we review the evolution of the PsA phenotype, from the Moll and Wright subtypes described in 1973 and how they might have chang

Psoriatic arthritis (PsA) develops in up to one-third of patients with psoriasis (PsC), yet increasing attention is now focused on a putative subclinical phase preceding overt arthritis. Several conceptual frameworks describe the PsC-PsA transition, including the pragmatic definition proposed by the European Alliance of Associations for Rheumatology, which defines subclinical PsA as arthralgia and/or imaging abnormalities in the absence of clinical synovitis. However, the absence of validated se

Psoriatic arthritis (PsA) is a complex, multisystem disease with no diagnostic criteria and discordant approaches to assessing disease activity and response to treatment. PsA is part of the Psoriatic Disease spectrum, encompassing cutaneous psoriasis and nail changes, PsA and in some cases, uveitis and inflammatory bowel disease. The HIPPOCRATES consortium is addressing unmet needs in PsA and has now established a harmonised data platform, the Secure HIPPOCRATES Data Management Platform (SHDMP),

Background Biologic agents are an important novel therapeutic option for moderate-to-severe psoriasis. In recent years, TikTok and Bilibili have gradually become important channels for Chinese patients to obtain health information. This study aims to evaluate the content, quality, reliability, and transparency of videos related to biologic therapy for psoriasis on these platforms.Methods We searched both platforms using the dual keywords "psoriasis" and "biological agents," confirmed compliance

Research suggests that healthcare professionals find it more difficult to correctly diagnose dermatological conditions in the nonwhite patient demographic. People of colour experience higher rates of delayed and misdiagnosis, contributing to an increased mortality risk and increased health inequalities that remain widespread throughout the health care setting. This study aimed to investigate podiatry student's ability, confidence, approaches and perceptions in diagnosing dermatology pathologies

Introduction Patients with moderate-to-severe psoriasis often experience significant physical symptoms and notable psychosocial distress. Pruritus is the most bothersome symptom and a key contributor to sleep disturbances and reduced quality of life (QoL). Though biologics such as risankizumab have advanced clinical management, real-world evidence of patient-reported outcomes (PROMs) and objective pruritus assessment remains limited. This study assessed risankizumab's effectiveness in improving

Psoriasis is a prevalent, autoimmune skin disease that easily relapses and is difficult to cure. Given its increased global prevalence and the limitations of synthetic therapies, developing of natural product-originated agents with fewer side effects and high therapeutic efficacy is of serious concern. Therefore, this work aimed to evaluate the potential effect of enzymatically-modified isoquercitrin (EMIQ, 50 and 100 mg/kg body weight "b.wt", administered orally for 8 days), in comparison with

To develop a unified diagnostic algorithm for axial psoriatic arthritis (axPsA). MATERIALS AND METHODS. : A total of 122 patients with psoriatic arthritis (PsA), duration less than 10 years, were included in the study according to CASPAR criteria, provided that they also had axial involvement. Axial involvement was detected in case of radiographic sacroiliitis [(rSI); bilateral grade ≥2 or unilateral grade ≥ 3] or active MRI SI (MRI-SI), or ≥ 1 syndesmophyte(s) of the cervical and/or lumbar spin

Background/Objectives: Psoriasis and periodontitis share inflammatory pathways. Current evidence suggests a bidirectional non-causal relation. However, the evidence on the effects of periodontal treatment on psoriasis outcomes (severity, inflammatory markers, quality of life) is limited. This study aims to synthetize the available clinical and preclinical evidence of periodontal treatment effects on psoriasis outcomes, in patients with comorbid psoriasis and periodontitis (CRD420261298145). Meth

No abstract supplied.Weiterlesen

Background Up to one-third of people living with psoriasis develop psoriatic arthritis (PsA), and the majority have active psoriasis prior to the development of arthritis. Clinical risk factors, such as nail involvement, in conjunction with novel blood biomarkers, could improve PsA risk monitoring and early diagnosis.Objectives The aim of the HIPPOCRATES Prospective Observational Study (HPOS-www.hpos.study) is to follow a cohort living with psoriasis and identify risk factors for the development

Psoriasis is a cutaneous autoimmune disease with worldwide prevalence. In situ activation of skin-infiltrating plasmacytoid dendritic cells (pDCs) leading to local induction of type I interferons (IFNs) is a crucial innate initiation event in psoriasis. Psoriatic patients also have notable susceptibility to the development of metabolic syndrome, especially systemic insulin resistance. Interestingly, a crucial role of systemic and metabolic tissue-restricted induction of type I IFNs is now establ

Psoriasis vulgaris is a common chronic inflammatory skin disease associated with hyperproliferation and defective differentiation of keratinocytes. Despite new effective treatments using biologicals targeting key cytokines or their receptors, innovative therapeutic approaches remain to be discovered. Here, psoriasis-like imiquimod-induced skin lesions in mice were improved when topically treated with a nano-sized, phosphorus-based dendrimer capped with azabisphosphonate groups, so-called IMD-006

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Background Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory diseases that affect not only the skin and joints but also the cardiovascular system.Aim To investigate the relationship between epicardial adipose tissue (EAT) thickness and anthropometric measurements, laboratory parameters, and clinical variables in patients with psoriasis and PsA.Methods This cross-sectional study included 65 patients with psoriasis vulgaris (with or without PsA) and 54 healthy controls. Demographic,

Psoriasis is a chronic, immune-mediated skin disease with well-studied genetic and immunologic drivers. Substantial unexplained variability remains, however, in disease onset, severity, and treatment response. There is evidence that implicates the role of environmental and social determinants in these observed differences in psoriasis. We conducted a systematic review to synthesize the current evidence examining the relationship between external exposures, including air and chemical pollution, t

Background Psoriasis is recognized as a systemic inflammatory disease associated with metabolic dysregulation. Understanding these metabolic changes may reveal biomarkers to elucidate disease mechanisms and predict comorbidities. While previous studies have identified psoriasis-associated metabolites, findings are often limited by sample sizes and lack validation.Objectives To identify circulating metabolites associated with psoriasis, including disease severity and psoriatic arthritis. Further,

Background Palmoplantar psoriasis exhibits greater treatment resistance compared to other psoriatic plaques and presents clinical and histopathological overlap with palmoplantar eczema. This study aimed to investigate treatment resistance mechanisms in palmoplantar psoriasis and assess the contribution of IL-17, IL-23, and IL-36α to the differential diagnosis of palmoplantar psoriasis and eczema. Immunohistochemical levels of these cytokines were measured in paired acral and non-acral psoriatic

Psoriasis is a chronic, immune‑mediated skin disorder characterized by keratinocyte hyperproliferation, inflammatory infiltrates and systemic comorbidities. While genetic predisposition and immune dysregulation are established contributors, recent advancements in high‑throughput omics technologies have provided deeper insights into the molecular complexity of psoriasis. The present review synthesized findings from various omics layers, genomics, epigenomics, transcriptomics, proteomics, metabolo